FY2025 · ended Dec 31, 2025 · Revenue $176.18M, +12.4% YoY · Filed Mar 5, 2026
Cryoport, Inc. (CYRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $176.2 million and net income of $78.3 million. Free cash flow was -$25.0 million. As of Sep 30, 2026 it held $393.1 million in cash and investments and $44.4 million in total debt.
Revenue (TTM)
$192.44M
+11.8% vs year-ago TTM
Net income (TTM)
$-41.30M
-157.9% vs year-ago TTM
Operating cash flow (TTM)
$11.00M
+173.4% vs year-ago TTM
Free cash flow (TTM)
$-18.81M
+39.7% vs year-ago TTM
EPS (TTM)
$-0.98
-177.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
49.86M
-0.1% vs prior year
Net cash
$348.66M
as of Sep 30, 2026
Operating margin
-20.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CYRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Brentwood, TN
- SEC filer status
- Accelerated filer
- SEC CIK
- 1124524
- Former names
- CRYOPORT SYSTEMS INC (until Oct 20, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2020 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $176.2M | $156.8M | $168.7M | $237.3M | $222.6M |
| Operating income | -$36.8M | -$121.7M | -$100.5M | -$31.9M | -$17.8M |
| Net income | $78.3M | -$114.8M | -$99.6M | -$37.3M | -$275.5M |
| Diluted EPS | $1.40 | -$2.49 | -$2.21 | -$0.93 | -$6.18 |
| Operating cash flow | -$8.6M | -$16.3M | -$757,000 | -$1.9M | $8.1M |
| Free cash flow | -$25.0M | -$33.6M | -$39.5M | -$24.0M | -$15.8M |
| Total assets | $765.0M | $703.5M | $957.7M | $1.0B | $1.1B |
| Total liabilities | $262.4M | $301.6M | $468.7M | $482.9M | $471.1M |
| Stockholders' equity | $502.6M | $401.9M | $489.0M | $555.8M | $641.8M |
| Cash and investments | $411.2M | $250.6M | $445.6M | $516.0M | $628.8M |
| Total debt | $44.4M | $51.2M | $36.0M | $28.8M | $21.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
| ARS | Annual report to shareholders | Apr 22, 2026 | Dec 31, 2025 |
All 1000 Cryoport, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.